UBS Group Raises United Therapeutics (NASDAQ:UTHR) Price Target to $475.00

United Therapeutics (NASDAQ:UTHR - Free Report) had its price target increased by UBS Group from $415.00 to $475.00 in a report issued on Wednesday,Benzinga reports. UBS Group currently has a buy rating on the biotechnology company's stock.

A number of other brokerages have also recently issued reports on UTHR. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Monday, December 30th. LADENBURG THALM/SH SH raised their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $378.36.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $4.28 during mid-day trading on Wednesday, hitting $366.61. 252,787 shares of the company's stock were exchanged, compared to its average volume of 246,857. United Therapeutics has a one year low of $208.62 and a one year high of $417.82. The business has a fifty day moving average price of $370.83 and a 200 day moving average price of $351.77. The company has a market cap of $16.37 billion, a PE ratio of 16.10, a P/E/G ratio of 1.05 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the company earned $5.38 EPS. The firm's revenue for the quarter was up 22.9% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics will post 25.22 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, Director Christopher Causey sold 510 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares of the company's stock, valued at approximately $1,384,115.25. This trade represents a 12.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,792 shares of the business's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $355.88, for a total value of $2,773,016.96. Following the sale, the chief financial officer now directly owns 5,884 shares in the company, valued at $2,093,997.92. The trade was a 56.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 142,422 shares of company stock worth $53,498,732. 11.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. ClariVest Asset Management LLC raised its position in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. USA Financial Formulas acquired a new stake in United Therapeutics in the 3rd quarter worth approximately $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $82,000. Finally, Values First Advisors Inc. purchased a new position in shares of United Therapeutics in the third quarter worth $90,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.